Adolescent mental health during covid-19 pandemics: a systematic review.

OBJECTIVES: The outbreak of the COVID-19 pandemic has had wide-ranging outcomes on adolescents' well-being. However, less attention has been paid to the adolescent's mental health during the pandemic. The pandemic may impair adolescents' mental health through stress spillover from other family members, contextual and policy changes, and the disruption of everyday life routines. Therefore, our research is motivated by a need to address the relative scarcity of research examining adolescent mental health during the pandemic. CONTENT: This systematic review was conducted through the medical database, Web of Science, Scopus, Medline, Embase, Google Scholar, and Cochrane databases for peer-reviewed, cross-sectional, cohort studies assessing the mental health status of adolescents during the Covid-19 virus pandemic from May 2020 till Dec 2022 without language restriction. Keywords were selected based on the Mesh terms and Emtree. SUMMARY: Studies on coronavirus have revealed many significant psychological effects on teens of all ages. The most commom problems were on the stress and anxiety, sleep disorders, depression, post-traumatic stress disorder. Risk factors were concidered as prior mental health problem, female sexuality, fear of covid-19, nutrition, physical activity and listening the covid 19 news. OUTLOOK: Considering the critical age of teenagers, the role of parents is vital. Health policy maker should support parents as a key factors to approprate care for adolescent. Parents should be educated on parenting methods during the covid pandemic to avoid irreparable damage of adolescent's mental health.

The first report of clonidine in vivo/in vitro effects on infertile women with polycystic ovary syndrome (in vivo/in vitro study).

The sympathetic nervous system (SNS) is hyperactive in women with polycystic ovary syndrome (PCOS). This study was designed in two sections: in vivo/in vitro with clonidine as the alpha-2 adrenoceptor (ADR-α2) agonist for modulating this hyperactivity. Eighty women with PCO participated in this randomised clinical trial (in vivo). A clonidine (0.1 mg) tablet was given twice a day for two months. Polycystic ovary morphology (PCOM) and pregnancy rate were the main outcome measurements. In the candidates for in vitro fertilisation (IVF), clonidine was added to the culture medium during IVF for two study groups (PCO-clonidine/PCO-without) and two control groups (egg donors-clonidine/egg donors-without). Our results showed that the pregnancy rate significantly was higher in the study group (p = .002). The mRNA expression of ADR-α1 and ADR-ß2 in PCO was higher than control group (p value <.001). But ADR-α1 expression in PCO-clonidine group decreased (p value = .042), the same as ADR-α2 expression. The intensity of this effect showed a pattern for ADR-α1

Effects of Coenzyme Q10 and Diamond Nanoparticles on Ischemia-Reperfusion-Induced Testicular Damages in Rats.

Background: Ischemia-reperfusion (I/R) induced by testicular torsion can damage the testicles. In the present study, we assessed the effects of coenzyme Q10 (CoQ10) and diamond nanoparticles on sperm parameters in I/R testes in rats. Materials and Methods: Forty-eight Wistar adult male rats were divided into eight groups: healthy control (Ch), diamond nanoparticle healthy control group (Ch+Dia), CoQ10 healthy control group (Ch+Q10), diamond nanoparticles+CoQ10 healthy control group (Ch+Q10+Dia), torsion/detorsion group (Ct), the Ct group that received diamond nanoparticles (Ct+Dia), the Ct group that received CoQ10 (Ct+Q10), and Ct group that received diamond nanoparticles and CoQ10 (Ct+Q10+Dia). The rats were euthanized, and we collected the semen from the epididymal tissues to evaluate sperm viability, motility, concentration, and morphology parameters. Results: The I/R of the testicles significantly reduced sperm concentration, motility, viability, and altered sperm morphology in the rats. However, the administration of CoQ10 significantly improved sperm parameters in the rats with testicular I/R. Diamond nanoparticles decreased the sperm parameters; however, simultaneous administration of diamond nanoparticles and CoQ10 led to improved sperm parameters. Conclusion: CoQ10 potentially appeared to have protective effects against the long-term side-effects of I/R in testes in rats. Co-administration of diamond nanoparticles with CoQ10 significantly improved sperm parameters and greatly reduced the negative effects of diamond nanoparticles alone. Therefore, green synthesis of nanoparticles with the use of antioxidants such as CoQ10 is recommended.

Comparing a biosimilar follitropin alfa (Cinnal-fⓇ) with Gonal-fⓇ in women undergoing ovarian stimulation: An RCT.

BACKGROUND: Advances in recombinant DNA technology led to the development of recombinant follitropin alfa. Recombinant human follicle-stimulating hormone products are used to stimulate follicular maturation. OBJECTIVE: To compare the efficacy and safety of a biosimilar-candidate recombinant human follicle-stimulating hormone (Cinnal-fⓇ; CinnaGen, Iran) with the reference product (Gonal-fⓇ; Merck Serono, Germany) in women undergoing ovarian stimulation for intracytoplasmic sperm injection (ICSI). MATERIALS AND METHODS: In this randomized controlled trial, a total sample size of 200 women (age < 35 yr, candidate for ICSI) was calculated. Participants began a pituitary downregulation protocol with buserelin. They received 150 IU daily of either Cinnal-fⓇ or Gonal-fⓇ from the second day of their cycle. The primary outcome of the study was the percentage of metaphase II (MII) oocytes. The secondary outcomes included the number and quality of oocytes retrieved, duration of stimulation, fertilization rate, embryo quality, the number of clinical and ongoing pregnancies, and the incidence of ovarian hyperstimulation syndrome (as an important safety marker). RESULTS: A total of 208 women were enrolled, of whom, 200 completed the study period. Ovarian stimulation with Cinnal-fⓇ resulted in a comparable percentage of MII oocytes as with Gonal-fⓇ (78.64% vs 80.02%, respectively; p = 0.81). No statistically significant difference was seen in the secondary outcomes between the groups. CONCLUSION: Cinnal-fⓇ proved non-inferior to Gonal-fⓇ, based on the percentage of MII oocytes in women aged < 35 yr undergoing ICSI. Our findings confirm that the efficacy and safety profiles of Cinnal-fⓇ and Gonal-fⓇ are similar.

Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: An RCT.

BACKGROUND: Both oral contraceptive pills (OCPs) and estradiol valerate (E2) have been used to schedule a gonadotropin-releasing hormone antagonist in vitro fertilization (IVF) cycles. Since the suppression of follicle-stimulating hormone by OCPs can stay 5-7 days after stopping the pills, it seems that starting the gonadotropin-releasing hormone (GnRH) after 6 days of pre-treatment discontinuation may be important in IVF outcomes. OBJECTIVE: The aim of the present study was to determine the number of mature oocyte and pregnancy rate of three pretreatment methods for fresh embryo transfer cycles. MATERIALS AND METHODS: In this randomized controlled trial, two-hundred ten women (18-35 yr and less than 2 previous IVF attempts) undergoing IVF with the GnRH antagonist protocol were randomized to the OCP, E2, and no pretreatment arms. OCP group (n=53) received OCP (ethinyl estradiol30 µg and levonorgestrel150 µg), E2 group (n=63) received 4 mg/day oral E2 (17ß-E2) for 10 days from day 20 of the previous cycle and GnRH antagonist stimulation was started 6 days after the interruption of OCP and E2. The control group (n =70) did not receive any pretreatment. RESULTS: No significant difference was observed in the mean number of the mature oocyte, endometrial thickness, and embryo quality. The pregnancy rate in E2 group was higher than the two other groups (42.9% vs 39.6% and 34.3% in OCP and control group, respectively), but the difference was not statistically significant (p=0.59). CONCLUSION: It seems OCP or E2 pretreatment could not improve the fresh IVF-embryo transfer outcomes.

Polycystic ovary syndrome and circulating inflammatory markers.

BACKGROUND: Human and experimental studies suggest that the sympathetic regulatory drive in the ovary may be unbalanced (hyperactivity) in polycystic ovary syndrome (PCOS). Dysfunctional secretion of interleukin (IL) -1 (α & ß) or related cytokines may thus be related to abnormal ovulation and luteinization. OBJECTIVE: The aim of this study was the evaluation of cytokines' pattern in PCOS women and discussion about the explanation of cross-talk between two super systems: sympathetic and immune systems and explanation sympatho-excitation and relationship with interleukins. MATERIALS AND METHODS: In this study, 171 PCOS women aged between 20-40 years were studied the. Their body mass index was <28. The patients were divided into two groups: study group (n=85, PCOS women) and control group (n=86 normal women). The blood sample was obtained on the 3rd day of menstruation cycle. IL-17, IL-1α, IL-1ß, and TNF-α concentrations were determined in both groups. RESULTS: The median serum level of IL-1α in the PCOS group was higher than the control group (293.3 and 8.0, respectively, p<0.001). Also, the median serum level of IL-1ß was higher than the control group (5.9 and 3.1 respectively). But the median serum of level IL-17 in women with PCOS was significantly lower than the control group (p<0.001). CONCLUSION: Our results confirm that PCOS is a low-level chronic inflammation.